🟢 Cue Biopharma is trading 7.94% up in after-hours trading after B. Riley initiated coverage with a Buy rating

Cue Biopharma is trading 7.94% up at $39.99 in after-hours trading after B. Riley initiated coverage with a Buy rating on September 18, 2026.

• B. Riley set an $83.00 price target, citing potential in CUE-221, encouraging chronic-hives data, and upcoming Phase 2 results.
• Regular-session closes were $37.05 on September 18 and $37.84 on September 17, extending a strong seven-day advance.
• Investing.com and GuruFocus support the catalyst.